{"id":20322,"date":"2023-10-03T17:21:56","date_gmt":"2023-10-03T15:21:56","guid":{"rendered":"https:\/\/ggba.swiss\/?p=20322"},"modified":"2023-10-03T17:21:56","modified_gmt":"2023-10-03T15:21:56","slug":"nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/","title":{"rendered":"Nagi Bioscience secures CHF 12.4 million to propel animal-alternative testing"},"content":{"rendered":"\n

Life sciences start-up Nagi Bioscience<\/a> has closed its Series A funding round with an oversubscribed investment of CHF 12.4 million, catapulting its vision of developing groundbreaking laboratory equipment that pioneers alternatives to animal testing. This substantial investment comes from reputable venture capital firms across Europe, emphasizing the boundless potential of Nagi Bioscience’s humane and innovative approach to drug discovery and toxicology testing.<\/p>\n\n\n\n

Marking its debut in the commercial market, Nagi Bioscience launched SydLab One<\/a> at the end of Q1 2023, gaining a foothold in the biopharma and agrochemical R&D sectors, among others. Matteo Cornaglia, CEO and Co-Founder of Nagi Bioscience, conveyed his gratitude towards the investors, stating, \u201cThe enthusiastic support from our new investors reflects our belief in Nagi\u2019s potential to disrupt the drug discovery and toxicology testing markets. This substantial investment is a testimony of the hard work, dedication, and passion of our incredible team and will be instrumental now in scaling-up the commercial organization and operations, while expanding R&D activities to strengthen Nagi\u2019s portfolio of innovative products.\u201d<\/p>\n\n\n\n

The funding round witnessed a collaborative effort co-led by Swisscanto and imec.xpand, with additional participation from Excellis Holding, Verve Ventures, and Z\u00fcrcher Kantonalbank. The investors share a collective enthusiasm for Nagi Bioscience’s revolutionary approach, which seeks to replace a broad spectrum of mammalian tests in various industries. Robert Schier, Senior Director of Swisscanto, accentuated, \u201cWe are very excited about Nagi\u2019s potential… The company and its technology are great examples of Swiss high-quality innovation and entrepreneurship.\u201d<\/p>\n\n\n\n

Stepping into new horizons<\/h4>\n\n\n\n

Collaborations have been a cornerstone in Nagi Bioscience\u2019s success journey, underpinning a close-knit relationship with customers to co-create solutions that genuinely address market needs. Frank Bulens, Partner of imec.xpand, highlighted, \u201cNagi is introducing a new standard for preclinical evaluation enabling the identification of interesting compounds faster and more cost-effective.\u201d<\/p>\n\n\n\n

The Series A round paves the way for Nagi Bioscience to delve into new markets, forge robust partnerships, and further disrupt the conventional biological testing paradigm.<\/p>\n","protected":false},"excerpt":{"rendered":"

Propelling the momentum towards humane, next-gen laboratory solutions, Nagi Bioscience has secured CHF 12.4 million to open doors to new markets and innovations.<\/p>\n","protected":false},"author":6,"featured_media":20323,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,908,894,911,886],"class_list":["post-20322","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-diagnostic","tag-financing","tag-pharma","tag-rd"],"acf":[],"yoast_head":"\nNagi Biosciences raises CHF 12.4 million | GGBa<\/title>\n<meta name=\"description\" content=\"Propelling the momentum towards humane, next-gen laboratory solutions, Nagi Bioscience has secured CHF 12.4 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nagi Biosciences raises CHF 12.4 million | GGBa\" \/>\n<meta property=\"og:description\" content=\"Propelling the momentum towards humane, next-gen laboratory solutions, Nagi Bioscience has secured CHF 12.4 million.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-03T15:21:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Nagi Bioscience secures CHF 12.4 million to propel animal-alternative testing\",\"datePublished\":\"2023-10-03T15:21:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/\"},\"wordCount\":343,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png\",\"keywords\":[\"Biotech\",\"Diagnostic\",\"Financing\",\"Pharma\",\"R&D\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/\",\"url\":\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/\",\"name\":\"Nagi Biosciences raises CHF 12.4 million | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png\",\"datePublished\":\"2023-10-03T15:21:56+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Propelling the momentum towards humane, next-gen laboratory solutions, Nagi Bioscience has secured CHF 12.4 million.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"Nagi Bioscience is at the cusp of redefining the landscape of next-generation drug discovery and chemical testing technologies, placing humane testing solutions within arm\u2019s reach of the global scientific community. | \u00a9 Nagi Bioscience\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nagi Bioscience secures CHF 12.4 million to propel animal-alternative testing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nagi Biosciences raises CHF 12.4 million | GGBa","description":"Propelling the momentum towards humane, next-gen laboratory solutions, Nagi Bioscience has secured CHF 12.4 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/","og_locale":"en_US","og_type":"article","og_title":"Nagi Biosciences raises CHF 12.4 million | GGBa","og_description":"Propelling the momentum towards humane, next-gen laboratory solutions, Nagi Bioscience has secured CHF 12.4 million.","og_url":"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-10-03T15:21:56+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Nagi Bioscience secures CHF 12.4 million to propel animal-alternative testing","datePublished":"2023-10-03T15:21:56+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/"},"wordCount":343,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png","keywords":["Biotech","Diagnostic","Financing","Pharma","R&D"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/","url":"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/","name":"Nagi Biosciences raises CHF 12.4 million | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png","datePublished":"2023-10-03T15:21:56+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Propelling the momentum towards humane, next-gen laboratory solutions, Nagi Bioscience has secured CHF 12.4 million.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png","width":1180,"height":811,"caption":"Nagi Bioscience is at the cusp of redefining the landscape of next-generation drug discovery and chemical testing technologies, placing humane testing solutions within arm\u2019s reach of the global scientific community. | \u00a9 Nagi Bioscience"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Nagi Bioscience secures CHF 12.4 million to propel animal-alternative testing"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/20322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=20322"}],"version-history":[{"count":2,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/20322\/revisions"}],"predecessor-version":[{"id":20327,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/20322\/revisions\/20327"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/20323"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=20322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=20322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=20322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}